# A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies

> **NCT03085173** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 39 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia (CLL)
- Relapsed
- Refractory

## Interventions

- **BIOLOGICAL:** EGFRt/19-28z/4-1BBL CAR T cells

## Key facts

- **NCT ID:** NCT03085173
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-03-15
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03085173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03085173, "A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03085173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*